The early assessment of the response to Nivolumab of renal cell carcinoma by FDG PET/CT
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000034674
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Not provided
Patients who meet any of the following are excluded from the study. (1) Poorly-controlled diabetes mellitus (fasting blood glucose >150mg/dL) (2) History of organ transplantation (including bone marrow transplantation) (3) History of malignancy except: (i) Curatively treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer (Ta, Tis and T1). (ii) Patients who had been disease free more for than 3 years after curative therapy (4) Pregnant and/or nursing woman, possibility of pregnancy (5) Patient treated simultaneously by other antineoplastic therapeutic or therapy purposing antitumor effect except for nivolumab examples: chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy, hyperthermia, surgery (6) any other cases who are regarded as inadequate for study enrollment by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method